



9381 Judicial Drive, Ste.180  
San Diego, CA 92121  
Tel: 858.202.4900  
Fax: 858.450-6849

## **NVENTA EXPANDS CLINICAL AND SCIENTIFIC ADVISORY BOARD**

**NOT FOR IMMEDIATE RELEASE**

**October 4, 2007**

**San Diego, California USA** – Nventa Biopharmaceuticals Corporation (TSX:NVN) today announced the expansion of its recently formed Clinical and Scientific Advisory Board (CSAB), adding three members with experience directly relevant to the Company’s development programs, including its lead HspE7 clinical program for human papillomavirus (HPV)-related diseases.

Strengthening its already robust CSAB, these distinguished advisors add even more depth in the fields of immunology and clinical research in HPV-related diseases. The new members include:

- Mark H. Einstein, MD, MSc: Assistant Professor, Director of Clinical Research, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Women’s Health, Albert Einstein College of Medicine and Montefiore Medical Center, New York. Dr. Einstein’s clinical focus is in the development of immunotherapeutics, primarily in the area of women’s health with a focus on HPV-related lesions.
- Warner K. Huh, MD: Assistant Professor, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama, Birmingham (UAB) and Associate Scientist, UAB Comprehensive Cancer Center. Dr. Huh’s expertise is in the development of clinical approaches for the treatment of cervical lesions resulting from HPV infection.
- Richard Ulevitch, PhD: Chairman, Department of Immunology, The Scripps Research Institute, San Diego, California. Dr. Ulevitch’s research is centered on understanding the innate immune system and the factors that contribute to the body’s identification of pathogens and the resulting immune responses.

Commenting on the expansion, Gregory M. McKee, Nventa’s President and Chief Executive Officer stated: “We feel very fortunate to be in a position to attract such a prestigious group of experts. These additional members complement our existing team nicely and we expect that they will provide outstanding guidance as we continue to advance our HspE7 and other programs forward.”

**About Nventa Biopharmaceuticals Corporation:**

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa Biopharmaceuticals Corporation, please visit the Company's website located at [www.nventacorp.com](http://www.nventacorp.com).

**Contact:**

Donna Slade  
Director, Investor Relations  
9381 Judicial Drive, Suite 180  
San Diego, CA USA 92121  
Dir: 858.202.4945  
[dslade@nventacorp.com](mailto:dslade@nventacorp.com)